Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

February 1, 2017
Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mike Ward, Informa Pharma Intelligence insight global director of content, how his company’s approach has potential to double brain cancer survival.
Previous Article
Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?
Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical ...

Next Video
Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception
Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Glob...